For Residual TNBC Post-Chemo, Capecitabine Should Be Offered

Описание к видео For Residual TNBC Post-Chemo, Capecitabine Should Be Offered

For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care. https://www.medscape.com/index/list_5...

Комментарии

Информация по комментариям в разработке